2. Gene
  3. Cdk2 - cyclin dependent kinase 2 Gene

Cdk2 - cyclin dependent kinase 2 Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：细胞周期蛋白依赖性激酶 2

种属: Rattus norvegicus

基因 ID: 362817 | 基因类型: protein coding

关于 Cdk2

Primary_assembly 7: 1,129,811-1,137,403 reverse strand.mRatBN7.2:CM026980.1

This gene has 2 transcripts (splice variants), 203 orthologues, 24 paralogues and is associated with 15 phenotypes. Biased expression in Thymus (RPKM 127.6), Spleen (RPKM 69.2) and 9 other tissues.

功能概要

该基因编码的蛋白可启动细胞周期蛋白结合活性和细胞周期蛋白依赖性蛋白丝氨酸/苏氨酸激酶活性。参与多个过程，包括细胞对胰岛素刺激的反应；对 cAMP 的反应；和对雌二醇的反应。位于细胞质和细胞核中。用于研究膜增生性肾小球肾炎。该基因的人类直系同源物与前列腺癌和肾细胞癌有关。与人 CDK2（细胞周期蛋白依赖性激酶 2）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables cyclin binding activity and cyclin-dependent protein serine/threonine kinase activity. Involved in several processes, including cellular response to Insulin stimulus; response to cAMP; and response to estradiol. Located in cytosol and nucleus. Used to study membranoproliferative glomerulonephritis. Human ortholog(s) of this gene implicated in prostate Cancer and renal cell carcinoma. Orthologous to human CDK2 (cyclin dependent kinase 2). [provided by Alliance of Genome Resources, Apr 2022]

Cdk2 基因产物(1)

mRNA Protein Name
NM_199501.2 NP_955795.1 cyclin-dependent kinase 2
基因本体论
  • 分子功能
  • 生物过程
分子功能 GO 注释 逻辑证据 参考文献 来源
enables cyclin binding IPI
IPI: 通过物理相互作用推断
15809057 RGD
enables cyclin-dependent protein serine/threonine kinase activity IDA
IDA: 通过直接分析推断
11823715 RGD
enables protein-containing complex binding IPI
IPI: 通过物理相互作用推断
10952244 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in DNA damage response IMP
IMP: 通过突变表型推断
19151707 RGD
involved in animal organ regeneration IEP
IEP: 通过表达模式推断
16534847 RGD
involved in cellular response to insulin stimulus IDA
IDA: 通过直接分析推断
15994754 RGD
involved in lens development in camera-type eye IEP
IEP: 通过表达模式推断
10620399 RGD
involved in response to cAMP IDA
IDA: 通过直接分析推断
15994754 RGD
involved in response to cadmium ion IEP
IEP: 通过表达模式推断
16730872 RGD
involved in response to electrical stimulus IDA
IDA: 通过直接分析推断
15607308 RGD
involved in response to estradiol IEP
IEP: 通过表达模式推断
16019103 RGD
involved in response to ethanol IEP
IEP: 通过表达模式推断
16689928 RGD
involved in response to toxic substance IEP
IEP: 通过表达模式推断
17343987 RGD
involved in response to xenobiotic stimulus IEP
IEP: 通过表达模式推断
17706465 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Cdk2 蛋白结构

STKc_CDK2_3

STKc_CDK2_3: cd07860 (2 - 333)

  • 0
  • 100
  • 200
  • 300
  • 346 a.a.
蛋白主名 其他名称

cyclin-dependent kinase 2

cell division protein kinase 2

cyclin dependent kinase 2-alpha

相关产品

Approval
生物活性分子 (7)
目录号 产品名 作用方式
纯度 是否罕见病
HY-16297A Abemaciclib Inhibitor 99.97% 是
HY-10492 Dinaciclib Inhibitor 99.36% 是
HY-16297 Abemaciclib methanesulfonate Inhibitor 99.95% 是
HY-B0402 Amantadine Inhibitor 99.90% 是
HY-B0402A Amantadine hydrochloride Inhibitor ≥98.0% 是
HY-B0263 Thiabendazole Inhibitor 99.77% 否
HY-B0402B Amantadine sulfate Inhibitor / 否
Clinical Phase
生物活性分子 (27)
目录号 产品名 作用方式
纯度 Phase
HY-10580 GSK 3 Inhibitor IX Inhibitor 99.74% Phase 4
HY-112272 Lerociclib Inhibitor 98.35% Phase 3
HY-10005 Flavopiridol Inhibitor 99.73% Phase 2
HY-30237 (R)-Roscovitine Inhibitor 99.84% Phase 2
HY-103712A Samuraciclib hydrochloride Inhibitor 99.98% Phase 2
HY-50940 AT7519 Inhibitor 99.76% Phase 2
HY-101212 Fadraciclib Inhibitor 99.78% Phase 2
HY-10006 Flavopiridol Hydrochloride Inhibitor 99.73% Phase 2
HY-13914 Roniciclib Inhibitor 98.09% Phase 2
HY-10424 Milciclib Inhibitor 99.90% Phase 2
HY-112272A Lerociclib dihydrochloride Inhibitor 98.11% Phase 2
HY-16559 Riviciclib hydrochloride 98.89% Phase 2
HY-103712B Samuraciclib hydrochloride dihydrate Inhibitor 99.08% Phase 2
HY-50943 AT7519 Hydrochloride Inhibitor 99.42% Phase 2
HY-103712 Samuraciclib Inhibitor / Phase 2
HY-16559A Riviciclib Inhibitor / Phase 2
HY-138293 SY-5609 Inhibitor 99.66% Phase 1
HY-10008 SNS-032 Inhibitor 99.54% Phase 1
HY-141680 CPS2 Inhibitor 99.33% Phase 1
HY-10012 AZD-5438 Inhibitor 99.85% Phase 1
HY-12871B Atuveciclib Inhibitor 99.80% Phase 1
HY-11001 PHA-793887 Inhibitor 99.25% Phase 1
HY-111361 FN-1501 Inhibitor 99.08% Phase 1
HY-15504 RGB-286638 Inhibitor 99.70% Phase 1
HY-15504A RGB-286638 free base Inhibitor 98.07% Phase 1
HY-137443 Ipivivint Inhibitor 99.65% Phase 1
HY-50940A AT7519 TFA Inhibitor 98.53% Phase 1
Pre-clinical Phase
生物活性分子 (149)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-12529 Ro-3306 Inhibitor 98.68% 否
HY-12302 Kenpaullone Inhibitor 98.20% 否
HY-103248 Toyocamycin Inhibitor 99.90% 否
HY-10329 JNJ-7706621 Inhibitor 99.91% 否
HY-124719 hSMG-1 inhibitor 11j Inhibitor 99.82% 否
HY-137894A Tagtociclib hydrate Inhibitor 99.95% 否
HY-130665 TL12-186 Inhibitor 99.63% 否
HY-15339 CVT-313 Inhibitor 99.90% 否
HY-101257 YKL-5-124 Inhibitor 98.79% 否
HY-15166 (E/Z)-Zotiraciclib Inhibitor 99.96% 否
HY-18340 (R)​-​CR8 Inhibitor 99.61% 否
HY-11009 CGP60474 Inhibitor 99.23% 否
HY-15004 AUZ 454 Inhibitor 99.57% 否
HY-130709 PROTAC CDK2/9 Degrader-1 Inhibitor 99.85% 否
HY-124760 hSMG-1 inhibitor 11e Inhibitor 99.81% 否
HY-114177 Ebvaciclib Inhibitor 99.98% 否
HY-127104 FMF-04-159-2 Inhibitor 99.48% 否
HY-15878 LDC000067 Inhibitor 98.09% 否
HY-18299A Purvalanol A Inhibitor 98.30% 否
HY-15275 BMS-265246 Inhibitor 98.92% 否
HY-18930 NU6300 Inhibitor 96.08% 否
HY-13461A PHA-767491 hydrochloride Inhibitor 99.49% 否
HY-10014 R547 Inhibitor 99.57% 否
HY-12445 Asnuciclib Inhibitor 99.76% 否
HY-18340A (R)-CR8 trihydrochloride Inhibitor 98.95% 否
HY-13266A BS-181 hydrochloride Inhibitor 99.80% 否
HY-18629 SU9516 Inhibitor 99.81% 否
HY-12280 THZ2 Inhibitor 99.03% 否
HY-117535 CDK2-IN-4 Inhibitor 98.07% 否
HY-X0150 JSH-150 Inhibitor 98.36% 否
HY-18299 Purvalanol B Inhibitor ≥97.0% 否
HY-144117 GFB-12811 Inhibitor 98.00% 否
HY-123772 CDK5 inhibitor 20-223 Inhibitor 99.78% 否
HY-112626 CDK12-IN-2 Inhibitor 99.36% 否
HY-119940 MC180295 Inhibitor 98.89% 否
HY-117203A CDK12-IN-E9 Inhibitor 99.97% 否
HY-15569 NU6102 Inhibitor 99.23% 否
HY-108136A Bisindolylmaleimide X hydrochloride Antagonist 98.90% 否
HY-145694 CDK5-IN-3 Inhibitor 98.00% 否
HY-W011428 Olomoucine Inhibitor 99.78% 否
HY-108359 Alsterpaullone Inhibitor 99.85% 否
HY-148062 RSS0680 98.03% 否
HY-101257B YKL-5-124 TFA Inhibitor 99.44% 否
HY-15889 AMG 925 Inhibitor 98.20% 否
HY-103647 K00546 Inhibitor 98.08% 否
HY-112460 CDK2-IN-3 Inhibitor ≥97.0% 否
HY-107419 NU6140 Inhibitor 99.07% 否
HY-103646 CK7 Inhibitor 99.72% 否
HY-139980 CDK9-IN-13 Inhibitor 99.22% 否
HY-112358 GW8510 Inhibitor 99.64% 否
HY-15166B (E/Z)-Zotiraciclib citrate Inhibitor 98.06% 否
HY-142076 CDK4/6-IN-15 Inhibitor 96.15% 否
HY-100600 BGG463 Inhibitor ≥98.0% 否
HY-19316 NU2058 Inhibitor 99.66% 否
HY-15241 NVP-LCQ195 Inhibitor 98.81% 否
HY-154851 GSK-3 inhibitor 3 Inhibitor 98.72% 否
HY-41076 Ca2+ channel agonist 1 Inhibitor 99.71% 否
HY-111207 CA224 Inhibitor 99.94% 否
HY-100429 CAN508 Inhibitor 99.59% 否
HY-N5072 Desmethylglycitein Inhibitor 98.98% 否
HY-153556 GW297361 Inhibitor 98.13% 否
HY-139328 CDK12-IN-5 Inhibitor 99.01% 否
HY-13816 NU6027 Inhibitor 99.04% 否
HY-15166A (E/Z)-Zotiraciclib hydrochloride Inhibitor 99.90% 否
HY-103712C Samuraciclib hydrochloride hydrate Inhibitor 99.88% 否
HY-12843 Bohemine Inhibitor 98.93% 否
HY-112468 PNU112455A hydrochloride Inhibitor 99.56% 否
HY-W019806 Lacto-N-fucopentaose I Activator ≥98.0% 否
HY-136726 CGP-82996 Inhibitor 98.12% 否
HY-112346 RGB-286147 Inhibitor 98.60% 否
HY-139011 IV-361 Inhibitor 99.60% 否
HY-13266 BS-181 Inhibitor 98.10% 否
HY-114903 (E/Z)-BIO-acetoxime Inhibitor / 否
HY-X0009A JSH-009 dimaleate Inhibitor / 否
HY-14372 BS-194 Inhibitor 99.36% 否
HY-148868A Akt1&PKA-IN-2 Inhibitor / 否
HY-15889A AMG 925 HCl Inhibitor / 否
HY-139329 CDK12-IN-6 Inhibitor 98.09% 否
HY-148868 Akt1&PKA-IN-1 Inhibitor / 否
HY-13461 PHA-767491 Inhibitor 99.85% 否
HY-151436 ZLMT-12 Inhibitor / 否
HY-151409 CDK1-IN-5 Inhibitor / 否
HY-151407 CDK1-IN-3 Inhibitor / 否
HY-157516 CDK2-IN-22 Inhibitor 98.64% 否
HY-143497 HDAC1/2 and CDK2-IN-1 Inhibitor / 否
HY-130981 FN-1501-propionic acid / 否
HY-130001 CDK9-IN-9 Inhibitor / 否
HY-110368 BS-181 dihydrochloride Inhibitor / 否
HY-155602 CDK2-IN-18 Inhibitor / 否
HY-147698 ZLHQ-5f Inhibitor / 否
HY-151984 CDK9-IN-22 Inhibitor / 否
HY-141685 3-Methylthienyl-carbonyl-JNJ-7706621 Inhibitor / 否
HY-139651 CDK2-IN-7 Inhibitor / 否
HY-148651 CDK2-IN-15 Inhibitor / 否
HY-150570 Carbonic anhydrase inhibitor 14 Inhibitor / 否
HY-155441 CDK2-IN-20 Inhibitor / 否
HY-144811 CDK2-IN-9 Inhibitor / 否
HY-164827 CDK2 degrader 3 Degrader / 否
HY-151898 CDK4/6-IN-14 Inhibitor / 否
HY-158170 CDK7-IN-28 Inhibitor / 否
HY-148214 CDK2/4/6-IN-2 Inhibitor / 否
HY-115943 Anticancer agent 30 Inhibitor / 否
HY-161595 CDK5-IN-4 Inhibitor / 否
HY-115942 Anticancer agent 29 Inhibitor / 否
HY-146276 CDK/HDAC-IN-2 Inhibitor / 否
HY-139327 CDK12-IN-4 Inhibitor / 否
HY-159805 CDK2-IN-31 Inhibitor / 否
HY-155787 SHR5428 Inhibitor / 否
HY-161708 PROTAC FLT3/CDKs degrader-1 Degrader / 否
HY-161463 CDK2-IN-28 Inhibitor / 否
HY-146253 CDK1/2/4-IN-1 Inhibitor / 否
HY-100035 PT-262 Inhibitor 99.21% 否
HY-145867 EGFR-IN-45 Inhibitor / 否
HY-156470 Multi-kinase-IN-6 Inhibitor / 否
HY-112363 Aloisine A Inhibitor / 否
HY-161690 EF-4-177 Inhibitor / 否
HY-159155 CDK2/4-IN-1 Inhibitor / 否
HY-154852 GSK-3 inhibitor 4 Inhibitor / 否
HY-161776 P-gp/CDK2-IN-1 Inhibitor / 否
HY-144810 CDK2-IN-8 Inhibitor / 否
HY-164664 CDK2-IN-30 Inhibitor / 否
HY-151580S CDK2-IN-14-d3 Inhibitor / 否
HY-160941 CDK2-IN-29 Inhibitor / 否
HY-168067 CDK-IN-14 Inhibitor / 否
HY-151071 TMX-3013 Inhibitor / 否
HY-163856 CDK7-IN-30 Inhibitor / 否
HY-145693 CDK5-IN-2 Inhibitor / 否
HY-162619 CDK9-IN-33 Inhibitor / 否
HY-150573 CDK2-IN-12 Inhibitor / 否
HY-162528 CDK12-IN-7 Inhibitor / 否
HY-147771 ZLWT-37 Inhibitor / 否
HY-147409 Ulecaciclib Inhibitor / 否
HY-149407 Multi-kinase-IN-4 Inhibitor / 否
HY-168513 ALK-IN-29 Inhibitor / 否
HY-142696 CDK6/PIM1-IN-1 Inhibitor / 否
HY-160556 CDK2-IN-26 Inhibitor / 否
HY-123034 CDKI-83 Inhibitor / 否
HY-151878 CDK7-IN-20 Inhibitor / 否
HY-162416 CDK7-IN-27 Inhibitor / 否
HY-151408 CDK1-IN-4 Inhibitor / 否
HY-148213 CDK2/4/6-IN-1 Inhibitor / 否
HY-150641 CDK-IN-9 Inhibitor / 否
HY-123826 CCT68127 Inhibitor / 否
HY-160643 CDK2-IN-27 Inhibitor / 否
HY-112403 (S)-Roscovitine Inhibitor / 否
HY-112450 Olomoucine II Inhibitor / 否
HY-123045 PNU-292137 Inhibitor / 否
HY-111932 Indirubin-5-sulfonate Inhibitor / 否
HY-111356 IIIM-290 Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Cdk2 NCBI NCBI:1017
Mus musculus Cdk2 NCBI NCBI:12566
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z